<DOC>
	<DOCNO>NCT03103087</DOCNO>
	<brief_summary>The purpose study determine benefit safety relugolix 40 mg daily co-administered low dose estradiol norethindrone acetate compare placebo 24 week heavy menstrual bleeding associate uterine fibroid . Additionally , study design evaluate benefit relugolix 40 mg daily 12 week follow 12 week relugolix 40 mg daily co-administered low dose estradiol norethindrone acetate compare placebo 24 week population .</brief_summary>
	<brief_title>LIBERTY 2 : Efficacy &amp; Safety Study Relugolix Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids</brief_title>
	<detailed_description>This study international phase 3 randomize , double-blind , placebo-controlled efficacy safety study evaluate 24 week oral daily relugolix 40 mg co-administered low-dose estradiol norethindrone acetate ( Group A ) 12 week daily oral relugolix 40 mg alone follow 12 week daily oral relugolix 40 mg co-administered low-dose estradiol norethindrone acetate ( Group B ) compare 24 week placebo ( Group C ) . Approximately 390 woman heavy menstrual bleeding associate uterine fibroid enrol study participate approximately 10 month . Participation include ~ 11 week screening period , 24 week treatment follow period ~ 30 day . A diagnosis uterine fibroid confirm screening period centrally-reviewed transvaginal and/or transabdominal ultrasound . Following successful completion Screening period study participant randomize Treatment Group A , B , C attend visit monthly ( ie , every 4 week ) . Safety assess throughout study monitor adverse event , vital sign , physical examination , clinical laboratory test , 12-lead electrocardiogram , assessment bone mineral density . All patient complete Week 24 visit , include woman randomize placebo , offer opportunity enroll open-label extension study eligible patient receive relugolix co-administered low-dose estradiol norethindrone acetate . Patients enroll extension study follow-up visit approximately 30 day end treatment ( ie , patient 's last dose study medication ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Is premenopausal female age 18 50 year old day sign date informed consent form ; 2 . Has regularlyoccurring menstrual period ≤ 14 day duration cycle 21 38 day start one menstrual period start next , patient history least 3 month prior Screening 1 visit ; 3 . Has diagnosis uterine fibroid confirm transvaginal and/or transabdominal ultrasound perform saline gel contrast screening period ; 4 . Has heavy menstrual bleeding associate uterine fibroid evidence menstrual blood loss ≥ 80 mL per cycle measure alkaline hematin method screen period . 1 . Has unexplained vaginal bleeding outside patient 's regular menstrual cycle ; 2 . Has weight exceeds weight limit DXA scanner ; 3 . Has history currently osteoporosis , metabolic bone disease , hyperparathyroidism , hyperprolactinemia , hyperthyroidism , anorexia nervosa , low traumatic ( stand position ) atraumatic fracture ( toe , finger , skull , face ankle fracture allow ) . A history successfully treat hyperparathyroidism , hyperprolactinemia , hyperthyroidism allow patient 's bone mineral density within normal limit ; 4 . Has history use bisphosphonates , calcitonin/calcitriol , ipriflavone , teriparatide , denosumab , medication calcium vitamin D preparation treat bone mineral density loss ; 5 . Has participant investigational drug device study within 1 month prior Screening .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>